Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Ultra-compact, low-cost plasmo-photonic bimodal multiplexing sensor platforms as part of a holistic solution for food quality monitoring (GRACED)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Partnership: Photonics (cPPP)
Countries involved: Italy,Germany,Spain,Italy,Italy,Cyprus,Greece,Hungary,Belgium,France,France,France,France,France
Call: Advancing photonics technologies and application driven photonics components and the innovation ecosystem (H2020-ICT-2020-2, 2020)
Start date: 2021-01-01
End date: 2024-06-30
Duration (months): 42.0
Total project cost (EUR): 4989480.0
EU funding (EUR): 4989480.0
Participants: 17
Project status: SIGNED

As consumer demand for fresh fruits and vegetables (F&V) continues to increase, so does the risk of microbiological and chemical contamination. Currently, inspections for F&V are carried out at the production site or the food processing facility, based also on regulatory requirements. In most cases these are inspections of random batches using laboratory techniques, which may require up to two or more days before getting results. The time and cost per analysis leads to reduced checks and thus, elevated risks, even in countries with very efficient control mechanisms. Furthermore, such analysis cannot take place in all parts of the value chain (due to time requirements, but also due to associated cost), including supermarkets or restaurants, which are critical points since this is where the consumer will get the products from. GRACED considers the aforementioned need and the limitations of current techniques and proposes a novel solution for contaminants detection in all stages of the F&V industry value chains. The heart of the proposed solution is a novel plasmo-photonic bimodal interferometric sensor, combined with low cost on-chip light generation, capable of simultaneously and quickly detecting different analytes of interest. The sensor will be part of holistic, modular solution that exploits unique engineering designs, IoT concepts and advanced data analytics, for the early detection of contaminations in the F&V value chains. The approach will be validated in different production & distribution systems: a) a conventional farming system in open-air farms and the follow-up steps of food processing for preparing cooked meals and frozen vegetable packages, b) a novel, urban farming ecosystem, producing F&V locally and using them in in-situ restaurants, c) a short value chain based on agro-ecology and direct distribution from farmers to consumers & restaurants, d) a semi-automatic farm producing mushrooms and distributing them to supermarkets & wholesalers.

Keywords: plasmonics,interferometers,on chip light generation,quantum dots,biosensors,analytical device automation,fruits and vegetables value chains,plasmo photonics
Friction stir welding UNiversal HEAD (FUN HEAD)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: France,France,France,France
Call: Design of special welding head for FSW process with automatic adjustable pin and welding force control system [SAT] (H2020-CS2-CFP08-2018-01, 2018)
Start date: 2019-04-01
End date: 2021-10-31
Duration (months): 31.0
Total project cost (EUR): 947523.42
EU funding (EUR): 701249.11
Participants: 4
Project status: CLOSED

The project aim is to design, manufacture and set up a special universal FSW head for all CNC machines. This FSW head will include a force control system and mechanisms to use retractable pin tool.

Keywords: friction stir welding,retractable pin,stationary shoulder,cnc machines,force control system,universal head
A novel smart grid architecture that facilitates high RES penetration through innovative markets towards efficient interaction between advanced electricity grid management and intelligent stakeholders (FLEXGRID)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: A single, smart European electricity grid
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Spain,Austria,Cyprus,Croatia,Norway,Norway,Greece,Denmark
Call: Research on advanced tools and technological development (H2020-LC-SC3-2019-ES-SCC, 2019)
Start date: 2019-10-01
End date: 2022-09-30
Duration (months): 36.0
Total project cost (EUR): 3889056.25
EU funding (EUR): 3889056.25
Participants: 14
Project status: CLOSED

Future smart grids require the effective interaction between energy markets and electricity grid management systems in order to introduce new services and mitigate risks introduced by high RES penetration. FLEXGRID envisages the orchestration and integration of: i) advanced electricity grid models and tools, ii) flexibility assets’ management tools, and iii) data analytics and accurate forecasts of the various markets and RES production, in order to guarantee cost-effective and stable electricity grids. Towards this end, FLEXGRID project proposes a holistic future smart grid architecture able to accommodate high RES penetration through the advancement, interaction and integration of: i) innovative models that are based on recent advances in game theory in order to quantify and highly improve the trade-off between the various future energy markets’ requirements (Real Time, Efficient, Strategy Proof, Competitive, Scalable, Fair and Privacy Protecting) and guarantee, theoretically and in practice, the “fairness” of the equilibrium points that energy markets reach, ii) grid system models that use optimization theory to achieve more efficient market clearing and Optimal Power Flow (OPF) algorithms to achieve scalability, in a way that must also be Low Overhead, Multi-period, Robust and Network Upgrade Planning Aware, and iii) innovative Business Models through the use of artificial intelligence, which can be exploited by modern Energy Service Providers (ESPs) and RES Producers (RESPs) to achieve economic and operational benefits through their efficient interaction with FLEXGRID’s advanced markets and electricity grid models. FLEXGRID will help: i) DSOs/TSOs manage safely and at low cost their electricity grid by interacting with ESPs and RESPs through novel flexibility market procedures, ii) modern ESPs become more competitive and sustainable,and iii) RESPs optimally compose and exploit their production in a risk-averse manner by making their RES generation dispatchable.

Keywords: flexibility marketplace,smart grid and energy markets interaction,advanced opf models,advanced pricing models,high res penetration
Antibiotic resistant bacteria and genes, associated with urban agriculture in Low and Middle Income Countries: Ecological and medical perspectives (ARBUATEM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-10-01
End date: 2017-10-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

About 20 million hectares of arable lands are irrigated with wastewaters in the world and almost nothing is known about the presence, evolution and dissemination of antibiotic resistant bacteria and antibiotic resistance genes in these fields, and their possible transmission to humans and animals via the food chain. The proposed project will address that scientific question by using analytical chemistry, flow cytometry, molecular biology, metagenomic approaches, and computational biology, in order to characterise antibiotic resistant bacterial community structures and antibiotic resistance genes in untreated wastewaters and the corresponding irrigated agricultural sites compared to control sites in low and middle income countries, as well as the influence of abiotic factors. The new scientific data arising from this project will help to determine the factors that drive resistance and can be minimized by developing strategies to prevent further spread of antibiotic resistant bacteria and antibiotic resistance genes worldwide. The fellow, with a strong background in Microbial ecology and Biochemistry, will conduct this project under the supervision of Prof Piddock, a medical microbiologist and expert in antibiotic resistance, at the University of Birmingham.

Keywords: antibiotic resistant bacteria,metagenomics,flow cytometry,wastewater,urban agriculture,lmics
Myeloid Cells: Investigating their Role for Immunotherapy in Cancer (MIRIC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-01-01
End date: 2025-03-01
Duration (months): 24.0
Total project cost (EUR): 203149.44
EU funding (EUR): 203149.44
Participants: 1
Project status: TERMINATED

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe with the estimated direct health cost increasing from €79 to €86 billion during 2005-2014. The emerging field of immune-checkpoint therapy (ICT) has demonstrated unprecedented responses in patients with several types of metastatic tumors that were previously resistant to available treatment options. However only ~13% of patients respond to the immunotherapy. I believe the primary reason for this is that most therapies are T cell directed and to achieve durable responses one must also engage the innate arm of the immune system. Myeloid cells constitute a major proportion of tumor infiltrating cells in human cancers and are essential for the induction of antigen specific T cell responses-cells which mediate anti-tumor immunity. Tim-3 is a check-point molecule that is not only expressed on T cells but also constitutively expressed on Dendritic cells, namely DC1, which are particularly adept at initiating protective anti-tumour immunity. A number of studies have highlighted the crucial role of DCs including analyses of The Cancer Genome Atlas showing that patient survival for many cancers correlates positively with the gene expression signature for DCs. Given the current activity in developing Tim-3 blocking agents for clinical translation, it is imperative that we have a full understanding of how modulation of Tim-3 affects the innate arm of the immune system. The aim of this proposal is to determine the cell-intrinsic and non cell-intrinsic effects of Tim-3 modulation in cancer. Furthermore we will analyze the cellular and transcriptional changes associated with tumour infiltrating DC after ICT with anti-Tim3. This proposal is highly interdisciplinary implementing single-cell 'omics' strategies and systems immunology approaches to further unravel the players and rules governing immune responses during malignancy.

Keywords: cancer,immunotherapy,dendritic cells,t cells,single cell rna sequencing
Late Clinical Development of KH176: an innovative orphan drug to reach mitochondrial disease patients & market (KHON2bTREAT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Netherlands
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-10-01
End date: 2022-06-30
Duration (months): 45.0
Total project cost (EUR): 3337525.0
EU funding (EUR): 2336267.5
Participants: 1
Project status: CLOSED

Mitochondrial diseases are chronic progressive disorders for which no cure exists, affecting approximately 250,000 patients worldwide. KH176 is a proprietary small molecule designed by the Dutch SME Khondrion BV to treat a large group of rare mitochondrial and related diseases. With KH176, a new redox-modulator, Khondrion aims to stall disease progression and revert clinical complaints in mitochondrial diseases; it corrects cellular consequences of mitochondrial dysfunction and has broad market potential. Khondrion’s management has >25 years experience in mitochondrial medicine, patient care and drug development, and is supported by highly experienced entrepreneurs. Since 2012, Khondrion completed preclinical, Phase 1&2a clinical, EMA&FDA orphan drug designation providing market exclusivity, and has a strong patent portfolio. Khondrion operates in a small but highly lucrative niche market. The addressable market for KH176 is 50,000-250,000 mitochondrial disease patients in Europe&US. Base-case cumulative revenue on KH176 is expected €35M by 2024, a return of >10 times this grant. Worldwide orphan drug sales are to increase at 11% CAGR to $209b in 2022; orphan drugs are projected to account for 21.4% of worldwide prescription sales by 2022 (excl. generics) from 6% in 2000. Worldwide, Khondrion is one of few SMEs devoted to develop a drug for mitochondrial diseases. Khondrion follows fast, risk-reduced development for KH176; first market approval in adult patients (MELAS/MIDD), entering expedited authorization for other mitochondrial diseases. As spin-out, Khondrion aims licensing KH176 for major indications (preclinical data on KH176 in genetic forms of Parkinson’s completed). Financing of this KHON2bTREAT project by the EIC SME instrument Phase 2 will enable Khondrion to perform the dose-finding clinical trial (Phase 2b) on KH176 in its patient population, reaching essential milestones for investor/co-development financing of the Phase 3 trial for market approval.

Keywords: rare disease,late stage drug,mitochondrial disease,market access,company growth,phase 2b clinical trial,fda orphan drug designation
Innovative in-line Raman analytical sensor for new upstream cell culture monitoring and quality control (CELLUP)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: France
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-2-2016-2017, 2017)
Start date: 2017-08-01
End date: 2019-12-31
Duration (months): 29.0
Total project cost (EUR): 1969553.75
EU funding (EUR): 1969553.75
Participants: 1
Project status: CLOSED

The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-line analytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and process control during the phases of process development, scale-up and manufacturing of vaccines and antibodies for human medicines based on eukaryote cells culture. This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients and metabolites during the mammalian cell culture inside the bioreactor. Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. The negative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phase and in terms of untapped production yield improvement. Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem by offering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor. Based on the needs expressed by several major industrial actors, the company has already developed a first product successfully evaluated and released end of 2016 under the name ProCellics. The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a new configuration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and a related software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success of this new methodology development is a cell culture activity carried internally by our company. The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years.

Keywords: cell culture,scale up and automation,vaccine and antibody production,process analytics,technology,process and quality control,bioprocess modelling development,cost effective,upstream
Centre for New Methods in Computational Diagnostics and Personalised Therapy (CECM)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Germany,Germany,Poland,Poland,United Kingdom
Call: Teaming Phase 1 (H2020-WIDESPREAD-04-2017-TeamingPhase1, 2017)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 399963.75
EU funding (EUR): 399963.75
Participants: 6
Project status: CLOSED

Kraków educates a large number of medical and IT professionals; its research hospitals are well recognised in the scientific community. Furthermore, the local entrepreneurial sector, with a significant number of life science companies, is steadily growing. In light of this evolution we propose to establish the Centre of Excellence for New Methods in Computational Diagnostics and Personalised Therapy. The Centre's mission comprises development of new computation-based solutions for diagnostics and therapy in daily healthcare to improve personalised patient treatment, enhanced growth of SMEs which deal with technologies and services for novel personalised diagnostics and treatment strategies, as well as strong advancement of algorithms, models and technologies involved in personalised medicine. The project aims to develop a Business Plan establishing the Centre and enabling it to operate in such a way as to achieve measurable success through introduction of a certain number of solutions based on computational models to clinical trials, development of a number of new market-ready products and services based on innovations, authoring highly cited scientific papers, obtaining patents and securing grants. The Plan will be based on the Polish Specialisation Strategy and will be elaborated by two Polish partners: Cyfronet AGH (experts in simulation and computing infrastructures for science) and Klaster LifeScience Kraków (top cluster of industry, academia and hospitals in the life sciences domain), in collaboration with the University of Sheffield and Insigneo Institute (experts in translation of in-silico modelling and simulations to clinics), Forschungszentrum Jülich (experts in innovative HPC and data techniques for science and industry) and Fraunhofer ISI (experts in systemic multi-domain solutions and innovation in medicine).

Keywords: simulation,in silico medicine,personalised healthcare,decision support,high performance computing
Artificial-Intelligence-Augmented Cooling System for Small Data Centres (ECO-Qube)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Reducing energy consumption and carbon foorpint by smart and sustainable use
Action type: Innovation actions
Countries involved: Germany,Spain,Spain,Switzerland,Sweden,Sweden,Türkiye,Türkiye,Türkiye,Netherlands,Netherlands
Call: Integrated design concepts for energy-efficient ICT in buildings (H2020-LC-SC3-EE-2020-1, 2020)
Start date: 2020-10-01
End date: 2024-09-30
Duration (months): 48.0
Total project cost (EUR): 3715370.0
EU funding (EUR): 2998988.75
Participants: 13
Project status: SIGNED

Artificial-Intelligence-Augmented Cooling System for Small Data Centres “ECO-Qube”; is a holistic management system which aims to enhance energy efficiency and cooling performance by orchestrating both hardware and software components in edge computing applications. ECO-Qube is a data driven approach which utilizes valuable unused data from active data centre components. Created big data is being used by an artificial intelligence augmented system which detects cooling and energy requirements instantaneously. ECO-Qube differentiates from conventional cooling systems which keep operating temperatures within a strict interval and do not evaluate measurable cooling performance. Unmeasured cooling performance leads underperformed airflow, thermal disequilibrium, and high energy consumption. On the contrary, ECO-Qube offers a zonal heat management system which benefits from Computational Fluid Dynamics (CFD) simulations to adapt cooling system for the best airflow and cooling performance with minimum energy consumption. Moreover, ECO-Qube realizes smart workload orchestration to keep the CPUs at their most energy efficient state and maintain the thermal equilibrium to reduce overheating risk. Sustainability is another priority for ECO-Qube’s smart energy management system (EMS), which is designed to track the energy demand and operate the energy supply in cooperation with building/district’s EMS. This synergy maximizes the energy supplied from renewable energy sources and minimizes the energy supplied from sources with big carbon footprint. ECO-Qube solution will be assessed in three different pilots from different climatic conditions to validate energy efficiency under different external variables.

Keywords: smart cooling system,smart scheduling for cpu workloads,zonal heat management system,waste heat reuse in small data centres